ST Pharm inks $56M deal to produce API for a US biotech

23rd January 2026 Uncategorised 0

ST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in a regulatory filing.

More: ST Pharm inks M deal to produce API for a US biotech
Source: fierce